Insider Selling: Novartis AG (NVS) Major Shareholder Sells 43,800 Shares of Stock
Novartis AG (NYSE:NVS) major shareholder Bioventures Ltd Novartis sold 43,800 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $1.92, for a total value of $84,096.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Bioventures Ltd Novartis also recently made the following trade(s):
- On Wednesday, March 13th, Bioventures Ltd Novartis sold 132,738 shares of Novartis stock. The shares were sold at an average price of $2.12, for a total value of $281,404.56.
Shares of NYSE:NVS opened at $93.29 on Friday. Novartis AG has a 52-week low of $72.30 and a 52-week high of $93.62. The company has a market capitalization of $212.57 billion, a P/E ratio of 18.33, a PEG ratio of 1.96 and a beta of 0.67. The company has a current ratio of 1.20, a quick ratio of 0.97 and a debt-to-equity ratio of 0.29.
The company also recently disclosed an annual dividend, which was paid on Wednesday, March 13th. Investors of record on Tuesday, March 5th were paid a $2.8646 dividend. The ex-dividend date of this dividend was Monday, March 4th. This represents a yield of 3.27%. This is a boost from Novartis’s previous annual dividend of $2.33. Novartis’s dividend payout ratio is 36.15%.
NVS has been the topic of a number of analyst reports. JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of Novartis in a research note on Wednesday, January 16th. Credit Suisse Group cut Novartis to a “sell” rating in a research note on Thursday, December 20th. Cowen raised Novartis from a “market perform” rating to an “outperform” rating and set a $100.00 target price on the stock in a research note on Monday, November 26th. Barclays cut Novartis from an “equal weight” rating to a “sell” rating in a research note on Friday, December 7th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $105.00 target price on shares of Novartis in a research note on Tuesday, December 11th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $90.94.
A number of large investors have recently made changes to their positions in NVS. AlphaMark Advisors LLC bought a new position in Novartis in the fourth quarter worth approximately $30,000. Laurel Wealth Advisors LLC purchased a new stake in Novartis during the fourth quarter worth $35,000. Executive Wealth Management LLC purchased a new stake in Novartis during the fourth quarter worth $36,000. Sonora Investment Management LLC lifted its holdings in Novartis by 93.9% during the fourth quarter. Sonora Investment Management LLC now owns 479 shares of the company’s stock worth $41,000 after buying an additional 232 shares during the period. Finally, Front Row Advisors LLC lifted its holdings in Novartis by 90.7% during the fourth quarter. Front Row Advisors LLC now owns 492 shares of the company’s stock worth $42,000 after buying an additional 234 shares during the period. 11.68% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/insider-selling-novartis-ag-nvs-major-shareholder-sells-43800-shares-of-stock/2897186.html.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Recommended Story: Fiduciary
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.